Angiochem's ANG1005 Shows Clinical Benefit and Prolonged Survival in Phase II Trial
MONTREAL, QC--(Marketwired - June 06, 2016) - Angiochem, a biotechnology company developing peptide-drug conjugates uniquely capable of crossing the blood-brain barrier, presented data during a platform presentation at the American Society of Clinical …